文献速递心力衰竭与心肌病

增强子遗传变异修饰心肌病基因表达与进展

Genetic Variation in Enhancers Modifies Cardiomyopathy Gene Expression and Progression.
PubMed 文献 · Circulation · 2021-01-22

研究通过表观基因组分析鉴定MYH7和LMNA的增强子,并在人诱导多能干细胞来源心肌细胞中验证功能;发现rs875908破坏TBX5结合基序并关联心肌病超声特征进展,提示增强子变异是非编码修饰因子。

要点

  • 增强子调控MYH7和LMNA表达,关键增强子影响MYH6向MYH7转换。
  • rs875908位于MYH7转录起始位点2kb增强子区,破坏TBX5结合基序。
  • rs875908与心肌病纵向超声特征相关,提示非编码变异修饰进展。

核心结论

  • 增强子调控心肌病基因表达,其基因组变异与心肌病随时间进展相关。

研究设计与样本

  • 研究整合心脏和心肌细胞表观基因组分析(含启动子捕获染色质构象信息)鉴定增强子。
  • 在人诱导多能干细胞来源心肌细胞中验证增强子功能。
  • 全基因组搜索增强子序列变异,并用生物样本库数据关联心肌病进展。

主要发现

  • 鉴定并验证了LMNA和MYH7的多个增强子,包括调控MYH6向MYH7表达转换的关键增强子。
  • 删除该关键增强子导致工程化心脏组织中MYH6剂量依赖性增加和收缩速率加快。
  • rs875908破坏T-Box转录因子5结合基序,位于MYH7转录起始位点2kb的增强子区。
  • 基因编辑去除含该变异的增强子显著降低人心肌细胞中MYH7表达。
  • 生物样本库数据显示rs875908与心肌病纵向超声心动图特征相关。

临床怎么用

  • 增强子变异可作为心肌病进展的非编码修饰因子,辅助风险分层。
  • 该整合方法适用于其他心脏基因的非编码变异鉴定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Inherited cardiomyopathy associates with a range of phenotypes, mediated by genetic and nongenetic factors. Noninherited cardiomyopathy also displays varying progression and outcomes. Expression of cardiomyopathy genes is under the regulatory control of promoters and enhancers, and human genetic variation in promoters and enhancers may contribute to this variability. METHODS: We superimposed epigenomic profiling from hearts and cardiomyocytes, including promoter-capture chromatin conformation information, to identify enhancers for 2 cardiomyopathy genes, MYH7 and LMNA. Enhancer function was validated in human cardiomyocytes derived from induced pluripotent stem cells. We also conducted a genome-wide search to ascertain genomic variation in enhancers positioned to alter cardiac expression and correlated one of these variants to cardiomyopathy progression using biobank data. RESULTS: Multiple enhancers were identified and validated for LMNA and MYH7, including a key enhancer that regulates the switch from MYH6 expression to MYH7 expression. Deletion of this enhancer resulted in a dose-dependent increase in MYH6 and faster contractile rate in engineered heart tissues. We searched for genomic variation in enhancer sequences across the genome, with a focus on nucleotide changes that create or interrupt transcription factor binding sites. The sequence variant, rs875908, disrupts a T-Box Transcription Factor 5 binding motif and maps to an enhancer region 2 kilobases from the transcriptional start site of MYH7. Gene editing to remove the enhancer that harbors this variant markedly reduced MYH7 expression in human cardiomyocytes. Using biobank-derived data, rs875908 associated with longitudinal echocardiographic features of cardiomyopathy. CONCLUSIONS: Enhancers regulate cardiomyopathy gene expression, and genomic variation within these enhancer regions associates with cardiomyopathic progression over time. This integrated approach identified noncoding modifiers of cardiomyopathy and is applicable to other cardiac genes.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Gacita AM, Fullenkamp DE, Ohiri J, et al. Genetic Variation in Enhancers Modifies Cardiomyopathy Gene Expression and Progression. Circulation. 2021. PMID: 33478249. doi:10.1161/CIRCULATIONAHA.120.050432

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。